Press releases

29 June, 2022

Regulatory

Abliva finishes SEK200M financing round with publication of rights issue outcome

Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva”) or the ”Company”) today announces that the new share issue with preferential rights for existing shareholders, announced by the Company on 1 June 2022 (th ...

1 June, 2022

Regulatory

Abliva decides on a SEK 200 million financing to fund Phase 2/3 study of KL1333 to interim analysis and bring in new global life science and institutional investors

The Board of Directors of Abliva AB (Nasdaq Stockholm: ABLI) (“Abliva” or the “Company”) has approved a directed issue of approximately SEK 150 million to several life science specialist and instituti ...

31 May, 202231 May, 2022

Regulatory

Abliva targets SEK 200 million raise to fund the KL1333 Phase 2/3 study to interim analysis

Abliva AB (Nasdaq Stockholm: ABLI) today announced that it intends to raise a financing round of SEK 200 million to provide the company with the capital necessary to run the Phase 2/3 study with KL133 ...

20 December, 2021

Regulatory

Abliva resolves on directed issue of convertibles amounting to SEK 26 million

The Board of Directors of Abliva AB (Nasdaq Stockholm: ABLI) (“Abliva” or “the Company”) has today resolved to issue convertibles corresponding to SEK 26 million, subject to the approval of an extraor ...

24 November, 2021

Regulatory

Abliva’s IND for clinical development of KL1333 approved by FDA

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced that the US Foo ...

19 May, 2021

Regulatory

Abliva reports positive clinical Phase 1a/b results for KL1333 including signs of efficacy in PMD patients

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases (PMD), today announced positive ...

30 March, 2021

Regulatory

Abliva has completed a directed new issue

Abliva AB (Nasdaq Stockholm: ABLI) (“Abliva” or “the Company”), a biopharmaceutical company in the clinical phase that develops drugs for the treatment of rare and serious primary mitochondrial diseas ...

30 March, 2021

Regulatory

Abliva investigates the prerequisites for carrying out a directed new issue

Abliva AB (Nasdaq Stockholm: ABLI) (“Abliva” or the “Company”) a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, toda ...

20 January, 2021

Regulatory

Abliva appoints Ellen Donnelly as new CEO as it enters a new stage in its development

9 September, 2020

Regulatory

Abliva intends to start a pivotal KL1333 study second half 2021

Abliva AB (Nasdaq Stockholm: ABLI) today announced that the company’s Board of Directors has decided to accelerate the KL1333 clinical program, with the intention to start a pivotal Phase II/III clini ...

5 May, 2020

Regulatory

NeuroVive publishes outcome in rights issue

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (”NeuroVive” or the ”Company”) today announces that the new share issue with preferential rights for existing shareholders, announced by the Company ...

22 April, 2020

Regulatory

NeuroVive makes a MSEK 20 directed share issue to leading Nordic life science investor Hadean Ventures

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (”NeuroVive” or the ”Company”) has today decided upon a directed issue of shares totaling around MSEK 20 to Hadean Ventures (“Directed Issue”). Hade ...